熱門資訊> 正文
Acrivon Therapeutics GAAP每股收益为-0.52美元
2024-08-13 21:51
- Acrivon Therapeutics press release (NASDAQ:ACRV): Q2 GAAP EPS of -$0.52.
- As of June 30, 2024, the company had cash, cash equivalents and marketable securities of $220.4 million,
-
More on Acrivon Therapeutics
- Acrivon Therapeutics: Can You Win In Clinical Trials With Selection Bias?
- Seeking Alpha’s Quant Rating on Acrivon Therapeutics
- Historical earnings data for Acrivon Therapeutics
- Financial information for Acrivon Therapeutics
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。